Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Community Practice Connections™: Exploitation of the DNA Damage Response and the Emerging Role of PARP Inhibition in Pancreatic Cancer

Release Date: March 27, 2020
Expiration Date: March 27, 2021
Media: Internet - based

Activity Overview

Poly (ADP-ribose) polymerase (PARP) inhibitors target alterations in genes associated with the DNA damage response (DDR). Actionable alterations in DDR-associated genes (BRCA1/2 or ATM) are commonly present in pancreatic cancer and multiple PARP inhibitors are in clinical development for these patients. Clinicians need to be aware of the mechanism of PARP inhibition, and the possible application of PARP inhibitors for the treatment of susceptible pancreatic tumors.

This Community Practice Connection program will include excerpts from a live symposium held at the 2020 ASCO Gastrointestinal Cancers Symposium. This symposium was presented by an expert panel and addressed mutations associated with deficiencies in the DDR, recommendations for testing to detect molecular aberrations, and the incorporation of DDR-targeting agents into treatment regimens as clinical trial data matures and agents are reviewed by the FDA.

This online activity focuses on practical aspects of clinical care, with some future-looking education, and is designed for those who did not attend the live symposium and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of pancreatic cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with pancreatic cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the mechanistic rationale for targeting DDR in the treatment of patients with pancreatic cancer
  • Outline evidence pertaining to biomarker studies that may guide the use of PARP inhibition in pancreatic cancer
  • Examine efficacy and safety results concerning trials that have evaluated PARP inhibition and other DDR-targeting strategies for patients with pancreatic cancer
  • Appraise the role of PARP inhibition strategies in the context of combination regimens and sequencing paradigms in pancreatic cancer management

Faculty, Staff, and Planners’ Disclosures


Eileen M. O’Reilly, MD
Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Director, Medical Initiatives
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Research funding to Memorial Sloan Kettering: ActaBiologica, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, MabVax Therapeutics, Parker Institute for Cancer Immunotherapy, Roche; Consultant: Bayer, BioLineRx, Celgene, Cytomx, Ipsen, Loxo Oncology, Merck, Polaris Pharmaceuticals, Silenseed, Targovax.

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Chair, ACCRU Research Consortium
Phoenix, AZ

Disclosures: Grant/Research Support: Abgenomics, Amgen, Array Biopharma, Bayer, Biomedical, Bristol-Myers Squibb, Boston Scientific, Celgene, Clovis Oncology, Genentech, Ipsen, lncyte, Eli Lilly and Company, Merck, Seattle Genetics; Consultant: Array BioPharma, Bayer, Genentech, Incyte, Ipsen, Merck; IDMC/DSMD (to self): 1Globe Health Institute, AstraZeneca, Exelixis, Eli Lilly and Company, PanCAN; Scientific Advisory Board: Immuneering Corporation, Imugene, Sun BioPharma.

Kim Reiss Binder, MD
Kim Reiss Binder, MD
Assistant Professor of Medicine
Perelman School of Medicine
Assistant Program Director
Hematology/Oncology Fellowship Program
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: Bristol-Myers Squibb, Clovis Oncology, Tesaro.

Shubham Pant, MD
Shubham Pant, MD
Associate Professor, Department of Investigational Cancer Therapeutics
Associate Professor, Department of Gastrointestinal Medical Oncology
Associate Director, Department of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: 4-D Pharmacy Management Systems, TYME.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By